

December 22, 2021

To the Office of Attorney General:

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July 1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2)(b) of § 4637 Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying the Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) within 3 calendar days following the release of Leqvio into the commercial market.

Please see table below:

NDC	Drug Product Description	Introduction to Market	WAC at Introduction
00078-1000-60	LEQVIO (Inclisiran) 284mg subcutaneous injection	December 22, 2021	\$3,250.00

Please feel free to contact us if you have any questions and/or require any additional information.

**Novartis Services, Inc.**

North America Public Affairs  
One Health Plaza  
Building 200, Office 720  
East Hanover, NJ 07936-1080  
USA